JP2010521484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521484A5 JP2010521484A5 JP2009553770A JP2009553770A JP2010521484A5 JP 2010521484 A5 JP2010521484 A5 JP 2010521484A5 JP 2009553770 A JP2009553770 A JP 2009553770A JP 2009553770 A JP2009553770 A JP 2009553770A JP 2010521484 A5 JP2010521484 A5 JP 2010521484A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- alkyl
- compound
- hydrogen
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 8
- -1 homopiperidinyl Chemical group 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 229940121649 protein inhibitor Drugs 0.000 claims 6
- 239000012268 protein inhibitor Substances 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 1
- 229940121759 Helicase inhibitor Drugs 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89499907P | 2007-03-15 | 2007-03-15 | |
| US60/894,999 | 2007-03-15 | ||
| PCT/US2008/056807 WO2008112863A1 (en) | 2007-03-15 | 2008-03-13 | Compounds for the treatment of hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521484A JP2010521484A (ja) | 2010-06-24 |
| JP2010521484A5 true JP2010521484A5 (enExample) | 2011-04-14 |
| JP5343011B2 JP5343011B2 (ja) | 2013-11-13 |
Family
ID=39522038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553770A Expired - Fee Related JP5343011B2 (ja) | 2007-03-15 | 2008-03-13 | Ｃ型肝炎の治療のための化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7538103B2 (enExample) |
| EP (1) | EP2121696B1 (enExample) |
| JP (1) | JP5343011B2 (enExample) |
| CN (1) | CN101679441B (enExample) |
| AT (1) | ATE494291T1 (enExample) |
| DE (1) | DE602008004317D1 (enExample) |
| ES (1) | ES2357076T3 (enExample) |
| WO (1) | WO2008112863A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2005049622A1 (ja) * | 2003-11-19 | 2007-06-07 | 日本たばこ産業株式会社 | ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| WO2009120745A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| EP2268643B1 (en) * | 2008-03-27 | 2014-08-06 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
| GB0413087D0 (en) * | 2004-06-11 | 2004-07-14 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| JP2008517986A (ja) | 2004-10-26 | 2008-05-29 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス薬としての四環式インドール誘導体 |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ATE469155T1 (de) * | 2006-05-25 | 2010-06-15 | Bristol Myers Squibb Co | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| JP2010513450A (ja) * | 2006-12-20 | 2010-04-30 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス性インドール |
-
2008
- 2008-03-11 US US12/046,286 patent/US7538103B2/en active Active
- 2008-03-13 CN CN200880016128XA patent/CN101679441B/zh not_active Expired - Fee Related
- 2008-03-13 WO PCT/US2008/056807 patent/WO2008112863A1/en not_active Ceased
- 2008-03-13 JP JP2009553770A patent/JP5343011B2/ja not_active Expired - Fee Related
- 2008-03-13 ES ES08732099T patent/ES2357076T3/es active Active
- 2008-03-13 DE DE602008004317T patent/DE602008004317D1/de active Active
- 2008-03-13 AT AT08732099T patent/ATE494291T1/de not_active IP Right Cessation
- 2008-03-13 EP EP08732099A patent/EP2121696B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010521484A5 (enExample) | ||
| JP2010515752A5 (enExample) | ||
| JP2010521481A5 (enExample) | ||
| JP2010521476A5 (enExample) | ||
| JP2010521483A5 (enExample) | ||
| JP2010521482A5 (enExample) | ||
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| JP2012504632A5 (enExample) | ||
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2012528161A5 (enExample) | ||
| UA88909C2 (ru) | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение | |
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| JP2012512169A5 (enExample) | ||
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| EP2374464A3 (en) | HCV N3S-NS4A protease inhibition | |
| WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2005037860A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2012504132A5 (enExample) | ||
| JP2010510234A5 (enExample) | ||
| JP2011523651A5 (enExample) | ||
| MY148123A (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| PL1615613T3 (pl) | Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C | |
| WO2010096462A1 (en) | Linked diimidazole derivatives | |
| JP2008530096A5 (enExample) | ||
| JP2012504126A5 (enExample) |